2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Blood Banking, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Women’s Health, Workforce, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

2565 Adaptive sampling nanopore sequencing enables simultaneous rapid epigenomic acute leukemia subtyping and comprehensive molecular diagnosis

Elizabeth Do, BS, Vivek Shastri, Research Assistant Professor2, Francisco Marchi, PhD3, Dina Khalaf, CLINICAL ASSOCIATE PROFESSOR4, Petr Starostik, MD5, Pedro V. B. Orsini, MD6, Jatinder K Lamba, PhD7
1 University of Florida College of Pharmacy, Gainesville, Florida, United States
2 University of Florida College of Pharmacy, Gainesville, Florida, United States
3 ALMA Genomics, Gainesville, Florida, United States
4 University of Florida College of Medicine, Gainesville, Florida, United States
5 University of Florida College of Medicine, Gainesville, Florida, United States
6 ALMA Genomics, Gainesville, Florida, United States
7 University of Florida College of Pharmacy, Gainesville, Florida, United States, University of Florida Health Cancer Institute, Gainesville, Florida, United States

Background: Accurate diagnosis and risk stratification of acute leukemias currently require multiple molecular assays, resulting in prolonged turnaround times and increased costs. Although DNA methylation is a robust determinant of leukemic lineage, molecular subtype, and prognosis, it is not routinely incorporated into clinical diagnostic workflows. We recently developed the Acute Leukemia Methylome Atlas (ALMA), a machine learning framework for rapid methylation-based leukemia classification and prognostication (Marchi et al., Nat Commun., 2025), together with a nanopore sequencing workflow for real-time methylation profiling to accelerate its clinical translation. While whole-genome sequencing provides sufficient DNA methylation coverage for epigenetic based subtyping, insufficient coverage of clinically relevant genes assessed by clinical labs is a limitation. We integrated adaptive sampling (AS) to selectively increase sequencing depth over predefined genomic regions during sequencing and evaluated whether AS could simultaneously provide sufficient whole-genome methylation data for rapid epigenetic classification using ALMA and publicly available classifiers (MARLIN and Lamprey) and generate high-coverage sequencing of clinically relevant genes for genomic, cytogenetic, and pharmacogenomic (PGx) profiling from a single assay.

Methods: Mechanically sheared genomic DNA from patients with AML, APL, ALL, or MDS treated at UF Health Shands Hospital (age range, 0.02–70 years) was sequenced on the ONT PromethION platform using ligation-based libraries. AS targeted a custom panel of 506 genes comprising leukemia hotspot regions, the UF GatorSeq panel, published AS targets, and clinically actionable PGx genes. Target regions included a 3-kb symmetric and 20-kb directional buffer, encompassing approximately 2.7% of the genome. Sequencing data were analyzed using ALMA v2, MARLIN v1, and Lamprey v0.1.0 to evaluate real-time methylation-based classification. Genomic and structural variants were determined using the ONT wf-human-variation pipeline, PGx genotypes and predicted phenotypes were assigned using PharmCAT v3.2.0, and digital karyotypes were inferred using NasVar and QDNAseq.

Results: Methylation-based classification was performed every 2 hours throughout sequencing of 12 samples and all three classifiers correctly identified 10 cases (83.3%) within 2–4 hours of sequencing. All classifications were stable through the end of sequencing. The only universally misclassified sample represented a suspected MECOM-rearranged AML, a rare subtype accounting for <2% AML cases and likely underrepresented in classifier reference datasets. Lamprey uniquely identified the GATA1-mutated AML with trisomy 21 case that was misclassified by ALMA or MARLIN, whereas ALMA and MARLIN correctly classified the CEBPA-mutated AML misclassified by Lamprey. AS simultaneously achieved high coverage across clinically actionable target regions, enabling comprehensive molecular characterization from the same assay. Clinically relevant mutations and structural alterations, including NPM1, FLT3-TKD, CEBPA, and KMT2A and MECOM rearrangements, all were concordant with conventional clinical testing results and supportive of the methylation-based subtype assignments. PGx analysis called genotype and predicted phenotypes for 19 of 20 clinically actionable PharmCAT genes, with the exception of CYP2D6 due to analytical limitations. All digital karyotypes generated were completely concordant with conventional cytogenetic analyses to match clinical karyotypes.

Conclusions: AS-enabled nanopore sequencing provides a unified molecular diagnostic platform capable of rapid methylation-based leukemia classification within 2–4 hours using all three currently available methylation classifiers. Comprehensive genomic, cytogenetic, and PGx information was successfully obtained from a single sequencing assay. Building upon the recently described ALMA framework, this integrated workflow has the potential to consolidate multiple molecular diagnostic tests into a single assay, substantially reducing diagnostic turnaround time while preserving clinically actionable information. Ongoing validation in an expanded cohort of 30–35 patients, including additional rare leukemia subtypes and updated versions of methylation classifiers, will further define diagnostic performance and support prospective clinical implementation of rapid epigenomic diagnostics for hematologic malignancies.

Elizabeth Do, BS: No relevant conflicts of interest to declare.